William B. White

Active 1958–2025

Also published as
William B White
117
Papers
32,904
Citations
87
h-index
116
i10-index

Citations

Citations per year for William B. White1964: 1 citations1966: 1 citations1967: 2 citations1969: 1 citations1970: 2 citations1971: 6 citations1972: 4 citations1973: 3 citations1974: 3 citations1975: 1 citations1976: 6 citations1977: 3 citations1979: 4 citations1980: 3 citations1981: 5 citations1982: 6 citations1983: 7 citations1984: 7 citations1985: 9 citations1986: 8 citations1987: 11 citations1988: 6 citations1989: 15 citations1990: 19 citations1991: 25 citations1992: 39 citations1993: 45 citations1994: 38 citations1995: 44 citations1996: 39 citations1997: 37 citations1998: 44 citations1999: 45 citations2000: 48 citations2001: 47 citations2002: 34 citations2003: 58 citations2004: 78 citations2005: 94 citations2006: 95 citations2007: 105 citations2008: 87 citations2009: 69 citations2010: 91 citations2011: 106 citations2012: 134 citations2013: 105 citations2014: 159 citations2015: 176 citations2016: 169 citations2017: 166 citations2018: 157 citations2019: 586 citations2020: 580 citations2021: 511 citations2022: 425 citations2023: 379 citations2024: 558 citations2025: 245 citations2026: 17 citations1965: no citations, so this year is not shown1968: no citations, so this year is not shown1978: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,210 citing papers, 24.8% of this breakdownUnited Kingdom: 616 citing papers, 6.9% of this breakdownChina: 529 citing papers, 5.9% of this breakdownItaly: 487 citing papers, 5.5% of this breakdownGermany: 418 citing papers, 4.7% of this breakdownJapan: 409 citing papers, 4.6% of this breakdownCanada: 387 citing papers, 4.3% of this breakdownFrance: 302 citing papers, 3.4% of this breakdownAustralia: 291 citing papers, 3.3% of this breakdownSpain: 285 citing papers, 3.2% of this breakdownNetherlands: 187 citing papers, 2.1% of this breakdownGreece: 153 citing papers, 1.7% of this breakdown
0%24.8%Other 29.6%

Fields

  • Medicine76.5%
  • Materials Science4.3%
  • Biochemistry, Genetics and Molecular Biology4.2%
  • Engineering3.6%
  • Neuroscience1.6%
  • Earth and Planetary Sciences1.5%
  • Other8.3%

Topics

  • Blood Pressure and Hypertension Studies8.5%
  • Diabetes Treatment and Management5.8%
  • Hormonal Regulation and Hypertension3.6%
  • Gout, Hyperuricemia, Uric Acid2.7%
  • Heart Rate Variability and Autonomic Control2.7%
  • Sodium Intake and Health2.6%
  • Other74.1%

Coauthors

All papers

Open in search
  1. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association

    Authors: , , , , , , , , , , , , , - Hypertension 2019 cited by 1,455

  2. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

    Authors: , , , , , , , , , , , , , , , , , - Hypertension 2018 cited by 1,074

  3. Non-viral precision T cell receptor replacement for personalized cell therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lindsey Skrdlant, Eva Yi-Hsuan Huang, Ventura F. Mendoza, Jyoti Mathur, Luke Dengler, Bhamini Purandare, Robert Moot, Michael C Yi, Roel Funke, Alison Sibley, Todd Stallings-Schmitt, David Y. Oh, Bartosz Chmielowski, Mehrdad Abedi, Yuan Yuan, Jeffrey A. Sosman, Sylvia M. Lee, Adam J. Schoenfeld, David Baltimore, James R. Heath, Alex Franzusoff, Antoni Ribas, Arati V. Rao, Stefanie Mandl - Nature 2022 cited by 278

  4. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

    Authors: , , , , , , , , - New England Journal of Medicine 2018 cited by 891

  5. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 2,524

  6. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , - The Lancet 2019 cited by 362

  7. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stefano Omboni, Paul L. Padfield, Paolo Palatini, Dario Pellegrini, Nicolas Postel‐Vinay, Agustín J. Ramiréz, James E. Sharman, Andrew Shennan, Eglé Silva, Jirar Topouchian, Camilla Torlasco, Ji Guang Wang, Michael A. Weber, Paul K. Whelton, William B. White, Giuseppe Mancia - Journal of Hypertension 2021 cited by 172

  8. Resistant Hypertension: Diagnosis, Evaluation, and Treatment

    Authors: , , , , , , , , , , , , , - Circulation 2008 cited by 2,238

  9. National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers.

    Authors: , , , , , , - Hypertension 1993 cited by 395

  10. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis

    Authors: , , , , , - Journal of the American Society of Hypertension 2014 cited by 452

  11. Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

    Authors: , , , , , , , , , , , , , , - JAMA 2011 cited by 516

  12. Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension

    Authors: , , , , , , , - Circulation 2011 cited by 213

  13. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

    Authors: , , , , , , , , , , , - The Lancet 2015 cited by 754

  14. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

    Authors: , , , , , , , , , - Journal of Hypertension 2011 cited by 278

  15. Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY)

    Authors: , , , , , , , , - Circulation 2019 cited by 119

  16. Nocturnal blood pressure measured by home devices

    Authors: , , , , , , , , , - Journal of Hypertension 2018 cited by 118

  17. Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

    Authors: , , , , , , , , , - Hypertension 2014 cited by 143

  18. Clinical Practice Guidelines for the Management of Hypertension in the Community

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Hypertension 2013 cited by 1,000

  19. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men

    Authors: , , , , , , , - The Journal of Clinical Endocrinology & Metabolism 2020 cited by 86

  20. Cardiovascular risk factors and small vessel disease of the brain: Blood pressure, white matter lesions, and functional decline in older persons

    Authors: , , , , , - Journal of Cerebral Blood Flow & Metabolism 2015 cited by 153

  21. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials

    Authors: , , , , , , , - Lara D. Veeken 2022 cited by 40

  22. Effects of eplerenone versus losartan in patients with low-renin hypertension

    Authors: , , , , , , , - American Heart Journal 2005 cited by 112

  23. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension

    Authors: , - Journal of the American Society of Hypertension 2008 cited by 126

  24. The Cave Environment

    Authors: , - Science 1969 cited by 572